Nasal Polyps Treatment Market Size, Share, and Growth Forecast 2026 - 2033

The global nasal polyps treatment market size is expected to be valued at US$ 4.3 billion in 2026 and is projected to reach US$ 7.0 billion, growing at a CAGR of 7.2% between 2026 and 2033.

Market growth is primarily driven by rising global prevalence of chronic rhinosinusitis with nasal polyps, combined with expanding clinical adoption of biologic therapies offering targeted symptom control beyond conventional corticosteroids. The World Health Organization (WHO) continues to identify chronic rhinosinusitis as a widespread upper airway condition affecting substantial adult populations globally, sustaining consistent demand for both first-line intranasal corticosteroids and advanced biologic treatments. Continued regulatory approval of monoclonal antibody therapies specifically indicated for nasal polyps further reinforces sustained treatment demand across both developed and emerging markets worldwide.

Drivers - Rising Global Prevalence of Chronic Rhinosinusitis with Nasal Polyps

Chronic rhinosinusitis with nasal polyps remains a persistent upper airway inflammatory condition affecting a meaningful share of adults worldwide, with epidemiological data published in peer-reviewed otolaryngology journals estimating that chronic rhinosinusitis affects a substantial proportion of the adult population across major healthcare markets. The Centers for Disease Control and Prevention (CDC) continues to report chronic sinusitis as a significant contributor to healthcare utilization and quality-of-life impairment in the U.S.

Aging populations and rising rates of asthma and allergic rhinitis, both closely associated comorbidities, continue to expand the diagnosed patient population eligible for nasal polyps treatment. The American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) continues to emphasize early diagnosis and structured treatment escalation as a cornerstone of chronic rhinosinusitis management, a clinical practice pattern that directly sustains recurring treatment demand.

Expanding Clinical Adoption of Biologic Therapies for Nasal Polyps

Biologic therapies targeting specific inflammatory pathways, including interleukin-4 and interleukin-13 receptor antagonists, continue gaining clinical traction as an add-on treatment option for patients with severe chronic rhinosinusitis with nasal polyps who remain symptomatic despite optimal corticosteroid and surgical management. The U.S. Food and Drug Administration (FDA)'s approval of dupilumab for chronic rhinosinusitis with nasal polyps has meaningfully expanded the treatment paradigm beyond conventional anti-inflammatory approaches, demonstrating substantial improvement in nasal polyp size and symptom scores in pivotal clinical trials.

The European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS) continues to update its clinical guidance to reflect growing evidence supporting biologic therapy use in appropriately selected patients. Companies including Sanofi S.A. and Regeneron Pharmaceuticals, Inc. continue to expand clinical and commercial investment in this biologic treatment category, reinforcing sustained physician and patient adoption momentum.

Restraints - High Treatment Costs Associated with Biologic Therapies

Biologic therapies for nasal polyps carry substantially higher treatment costs compared with conventional corticosteroid and antihistamine alternatives, creating access barriers for patients in healthcare systems with limited reimbursement coverage or significant out-of-pocket cost-sharing requirements. Payers frequently require documented treatment failure with conventional therapy and surgical intervention before approving biologic coverage, adding administrative complexity and treatment delays. This cost barrier compels healthcare systems to implement prior authorization requirements before approving biologic therapy, tempering near-term uptake despite strong clinical evidence supporting improved patient outcomes among appropriately selected candidates with severe disease.

High Recurrence Rates Following Surgical and Pharmacological Intervention

Nasal polyps frequently recur even after successful pharmacological treatment or surgical removal, a persistent clinical challenge that complicates long-term disease management and often necessitates repeated treatment courses or revision surgery. Clinical literature published in peer-reviewed otolaryngology journals continues to document meaningful recurrence rates among patients treated with corticosteroids or endoscopic sinus surgery alone, underscoring the condition's chronic, relapsing nature. This recurrence pattern increases the cumulative cost and treatment burden associated with nasal polyps management, complicating physician treatment planning and tempering the durability of single-modality treatment approaches across the broader patient population.

Opportunities - Development of Next-Generation Biologic Therapies Targeting Additional Inflammatory Pathways

Continued clinical trial investment in next-generation biologic therapies targeting alternative inflammatory pathways beyond interleukin-4 and interleukin-13 presents a significant opportunity for pharmaceutical companies to expand treatment options for patients who respond inadequately to currently available biologic agents. Companies including AstraZeneca PLC and Novartis AG continue to advance biologic pipelines targeting additional cytokine pathways implicated in chronic rhinosinusitis with nasal polyps pathophysiology.

Regulatory agencies have continued approving expanded biologic indications as post-marketing clinical evidence accumulates, broadening the addressable patient population eligible for advanced therapy. As biologic therapies continue capturing share from conventional corticosteroid and surgical approaches, pharmaceutical companies with differentiated, next-generation biologic pipelines are positioned to capture meaningful incremental demand within this rapidly expanding treatment category over the forecast period.

Expansion of Biologic Treatment Access Across Emerging Healthcare Markets

Growing healthcare infrastructure investment and expanding health insurance coverage across Asia-Pacific and Latin America are creating substantial headroom for nasal polyps biologic treatment volume growth beyond already-mature Western markets. Generic pharmaceutical manufacturers, including Sun Pharmaceutical Industries Ltd. and Cipla Ltd., continue to expand affordable corticosteroid and antihistamine formulation availability across price-sensitive emerging markets, broadening baseline treatment access ahead of eventual biologic therapy introduction.

As regulatory approval pathways for biologic therapies continue to mature across emerging healthcare markets, and as domestic manufacturing capability for both conventional and advanced nasal polyps treatments continues to expand, companies with established regional distribution networks are positioned to capture a disproportionate share of incremental prescription volume growth over the coming decade.

Treatment Type Insights

Corticosteroids are the leading treatment type segment, holding around 52% share of the nasal polyps treatment market in 2026, owing to their status as first-line therapy recommended across major clinical guidelines for chronic rhinosinusitis with nasal polyps management. The European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS) continues to recommend intranasal and, in select cases, systemic corticosteroids as the foundational treatment approach before escalation to biologic or surgical intervention. Corticosteroids' well-established safety profile, broad generic availability, and proven efficacy in reducing polyp size and nasal inflammation reinforce their continued first-line role across primary care and specialist otolaryngology settings.

Manufacturers including GSK plc and Teva Pharmaceutical Industries Ltd. maintain extensive corticosteroid product portfolios serving this broad-based demand. As global diagnosis and treatment of chronic rhinosinusitis continue expanding, corticosteroids are expected to retain their leading treatment type position through the forecast period.

Biologics represent the fastest-growing treatment type segment, supported by increasing adoption among patients with severe or uncontrolled chronic rhinosinusitis with nasal polyps who remain inadequately controlled with corticosteroids or require repeated surgery. Growing clinical evidence supporting targeted therapies, expanding regulatory approvals, and the availability of injectable biologics targeting specific inflammatory pathways are strengthening physician adoption. Continued investment by leading pharmaceutical companies in next-generation biologic therapies is also expected to accelerate segment growth through 2033.

Route of Administration Insights

Nasal is the dominant route of administration, reflecting the status of intranasal corticosteroid sprays as the standard first-line treatment across major chronic rhinosinusitis management guidelines. Nasal delivery allows direct application of anti-inflammatory medication to affected nasal and sinus tissue, supporting localized therapeutic action while limiting systemic exposure compared with oral or parenteral alternatives.

This localized delivery advantage, combined with the ease of long-term self-administration offered by nasal sprays for chronic maintenance therapy, continues to reinforce physician and patient preference for this administration route. As corticosteroids continue to represent the largest treatment type by prescription volume, nasal administration is expected to retain its leading route of administration position through the forecast period, even as parenteral administration gains share alongside the expanding adoption of injectable biologic therapies.

North America Nasal Polyps Treatment Market Insights

North America is expected to hold the largest market share of 40% in 2026, supported by high disease awareness, widespread access to otolaryngology specialists, favorable reimbursement for biologics, and early adoption of advanced therapies. The region benefits from well-established clinical guidelines for chronic rhinosinusitis with nasal polyps (CRSwNP) and rapid uptake of biologics such as dupilumab, omalizumab, mepolizumab, and tezepelumab. Chronic rhinosinusitis with nasal polyps affects an estimated 4.2% of the U.S. population, while chronic rhinosinusitis overall affects two to 16% of Americans, creating a large treatment pool.

Around 25% to 30% of chronic rhinosinusitis patients develop nasal polyps, increasing demand for long-term pharmacological management. Continuous FDA approvals of novel biologics, high healthcare expenditure, and broad insurance coverage for specialty medicines further strengthen regional market leadership.

U.S. Nasal Polyps Treatment Market Insights

The U.S. is expected to remain the largest contributor to the North American nasal polyps treatment market. The country benefits from one of the world's most advanced ENT care infrastructures and early commercialization of innovative biologics. Studies indicate that chronic rhinosinusitis with nasal polyps has an estimated prevalence of 4.2% in the U.S., with the disease occurring most frequently among adults aged 40 to 60 years.

Patients with CRSwNP commonly require repeated corticosteroid therapy and endoscopic sinus surgery, driving demand for newer biologics that reduce recurrence. FDA approvals for Dupixent, Xolair, Nucala, and Tezspire have significantly expanded treatment options. High healthcare spending, favorable reimbursement, and strong physician adherence to evidence-based treatment guidelines continue to support the country's market leadership.

Canada Nasal Polyps Treatment Market Insights

Canada is expected to be the fastest-growing market within North America, registering an estimated 7.8% CAGR through 2033. Increasing diagnosis rates, broader access to biologic therapies through provincial reimbursement programs, and expanding specialist ENT services are driving market growth. Canadian health assessments estimate that chronic rhinosinusitis affects four to six percent of the adult population, with 25% to 30% of these patients developing nasal polyps.

Recent reimbursement evaluations for dupilumab and other biologics have improved treatment accessibility for patients with severe CRSwNP who remain uncontrolled despite corticosteroids or surgery. Rising physician awareness of biologic therapy and increasing adoption of minimally invasive sinus surgery are expected to sustain Canada's strong growth trajectory over the forecast period.

Europe Nasal Polyps Treatment Market Insights

Europe represents the second-largest regional market due to its high prevalence of chronic rhinosinusitis, universal healthcare systems, and well-established clinical management guidelines under the European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS). Chronic rhinosinusitis affects an estimated 10.9% of the European population, while CRSwNP prevalence is estimated at around 4.3%, supporting a substantial patient base requiring long-term treatment. The region has witnessed increasing adoption of biologic therapies following regulatory approvals and reimbursement expansion across major healthcare markets.

Strong investments in respiratory and immunology research, together with increasing availability of ENT specialists and endoscopic sinus surgery, further strengthen regional demand. Growing awareness of type-2 inflammatory diseases and increasing use of personalized medicine are expected to support regional market growth.

Germany Nasal Polyps Treatment Market Insights

Germany is a major contributor to the European market. The country benefits from one of Europe's strongest healthcare systems, extensive reimbursement coverage, and widespread adoption of biologic therapies. Germany has a high burden of chronic rhinosinusitis and follows EPOS recommendations for diagnosis and treatment, enabling rapid adoption of advanced biologics for severe CRSwNP. A large network of ENT specialists, university hospitals, and outpatient surgical centers supports early diagnosis and comprehensive disease management. Strong pharmaceutical presence and participation in clinical research involving biologics further reinforce Germany's leadership within the European nasal polyps treatment market.

U.K. Nasal Polyps Treatment Market Insights

The U.K. is expected to hold a significant share of the European market in 2026. Increasing NHS adoption of biologic therapies for severe CRSwNP, growing awareness among healthcare professionals, and expanding use of multidisciplinary respiratory care are key growth drivers. The NHS has progressively incorporated biologics into treatment pathways for patients inadequately controlled by surgery and corticosteroids. Rising prevalence of asthma and allergic diseases, which frequently coexist with nasal polyps, also contributes to increasing treatment demand. Continued investment in specialist ENT services and wider access to innovative therapies are expected to accelerate market expansion throughout the forecast period.

Asia Pacific Nasal Polyps Treatment Market Insights

Asia Pacific is projected to register the fastest growth over the forecast period, owing to expanding healthcare infrastructure, increasing disease awareness, improving diagnostic capabilities, and growing availability of biologic therapies. Large populations, rising healthcare expenditure, and increasing incidence of chronic inflammatory airway diseases are creating significant opportunities for pharmaceutical manufacturers. Studies report chronic rhinosinusitis prevalence of an estimated eight percent in China and 6.9% in South Korea, while improved diagnosis across the region is expanding the identifiable patient population.

Governments around the region are investing heavily in healthcare modernization, and multinational pharmaceutical companies continue to launch innovative biologics across key Asian markets. Increasing access to health insurance and greater availability of ENT specialists are expected to drive strong regional market growth in the coming years.

China Nasal Polyps Treatment Market Insights

China is the largest market in Asia Pacific. The country's large patient population, expanding tertiary hospitals, and rapidly improving access to specialty healthcare support sustained market growth. Epidemiological studies estimate chronic rhinosinusitis prevalence at around eight percent, while increasing urbanization, air pollution, and allergic diseases continue to contribute to disease burden. China has accelerated approvals of innovative biologics and expanded reimbursement for selected specialty medicines, improving patient access. Continuous investment in hospital infrastructure, physician training, and respiratory disease management is expected to further strengthen China's leadership within the Asia Pacific market.

India Nasal Polyps Treatment Market Insights

India is emerging as a significant market within Asia Pacific. Growth is supported by improving access to ENT specialists, expanding private healthcare infrastructure, rising diagnosis of chronic rhinosinusitis, and increasing availability of affordable generic corticosteroids and biologics. Government initiatives aimed at strengthening healthcare infrastructure, coupled with growing health insurance penetration, are enabling broader access to advanced treatments.

Rising levels of air pollution, allergic respiratory disorders, and urbanization are also contributing to increasing disease burden. Expansion of multinational pharmaceutical companies and domestic manufacturers offering biologics and specialty respiratory therapies is expected to support sustained market growth over the forecast period.

The global nasal polyps treatment market remains moderately consolidated, dominated by established multinational pharmaceutical companies with extensive respiratory and immunology drug portfolios alongside a growing base of generic manufacturers. Sanofi S.A. and Regeneron Pharmaceuticals, Inc. maintain leadership within the biologic treatment segment through their jointly developed monoclonal antibody therapy, while AstraZeneca PLC and Novartis AG continue to invest in next-generation biologic pipeline development.

Generic manufacturers including Teva Pharmaceutical Industries Ltd. and Viatris Inc. compete aggressively on price within the corticosteroid and antihistamine segments. Emerging competitive strategies include expanded biologic indication development, combination-therapy research, and continued generic portfolio expansion across emerging markets.

Key Industry Developments

• October 2025: AstraZeneca and Amgen announced that the U.S. Food and Drug Administration (FDA) approved Tezspire (tezepelumab-ekko) as an add-on maintenance treatment for adults with chronic rhinosinusitis with nasal polyps (CRSwNP).
• November 2025: Regeneron Pharmaceuticals and Sanofi announced that Dupixent (dupilumab) met all primary and secondary endpoints in the pivotal Phase 3 LIBERTY-AFRS-AIMS trial for allergic fungal rhinosinusitis (AFRS).